arob (arob1000)

New data from our prostate cancer T-Cell Engager was just released and it is significantly helped 82% of patients with aggressive metastatic prostate cancer who were out of options with some patients showing lasting tumor regression with few mild side effects. It’s days like this that keep be engaged in my work…I was involved with the development of this drug since it was just an idea 💡, it’s great to see it transforming patients lives and very exciting to have such positive clinical trial results. 🧬 🧪 More info here if anyone is interested. https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Reports-Positive-Updated-Phase-1-Results-for-PSMA-targeting-PRO-XTEN-Dual-masked-T-Cell-Engager-VIR-5500-in-Patients-with-Metastatic-Prostate-Cancer/default.aspx

• 4 replies
• 7 recasts
• 33 reactions

Took some Berkeley college students on a lab tour yesterday. It’s always fun to get young people excited about /science and the many ways /science can translate into real-world impact.

• 0 replies
• 0 recasts
• 3 reactions

Not following $UCI too closely but the fact that it brings back floaties makes me hammish 🍖

• 4 replies
• 0 recasts
• 13 reactions

GM! I wanted to use my $BETR this week to support artists so let’s do a $BETR Art Share 🥇 500,000 $BETR 🥈 250,000 $BETR 🥉 100,000 $BETR To enter quote-cast this post with your art (any media as long as you made it) and reply with your quoted post. Art is one of the things I’ve been missing on the timeline and I’d love to see more!

• 85 replies
• 23 recasts
• 121 reactions

It’s been a few months since this post but with $BRACKY hitting an ATH today I figured it was time to resurface it. I’ve been actively trading on @bracky and have ~125,000,000 $BRACKY in my trading wallet plus active positions. The $7 airdrop is now worth ~$21,000 a ~3000x. A lot has changed in the past 3 months but my conviction in @tldr @passafiume.eth and the @bracky devs and community has never been higher and we’re just getting started.

• 25 replies
• 16 recasts
• 87 reactions

Very excited to announce that we’ve dosed our first patient with our latest next-gen cancer immunotherapy drug which is broadly applicable to most solid tumors! We started working on this one in 2022. It’s really cool to see how quickly a drug can go from an idea into the clinic. https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-EGFR-Targeting-PRO-XTEN-Dual-Masked-T-Cell-Engager-VIR-5525-for-the-Treatment-of-Solid-Tumors/default.aspx

• 15 replies
• 13 recasts
• 70 reactions

I’d appreciate any boosts…never thought I’d get close to the top 30, my prior high rank was #70 last week which was by far my highest rank. Let’s make the number go up!

• 42 replies
• 17 recasts
• 59 reactions